AI assistant
Sending…
Atea Pharmaceuticals, Inc. — Director's Dealing 2020
Nov 4, 2020
33577_dirs_2020-11-03_9ec6ad8f-e479-4f7e-bbb8-e858b123f30d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2020-11-03
Reporting Person: Corcoran Andrea (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-11-03 | Common Stock | C | 133004 | — | Acquired | 633004 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-11-03 | Series A Convertible Preferred Stock | $ | C | 100000 | Disposed | Common Stock (100000) | Direct | |
| 2020-11-03 | Series B Convertible Preferred Stock | $ | C | 33004 | Disposed | Common Stock (33004) | Direct |
Footnotes
F1: The preferred stock was convertible at any time, at the holder's election and had no expiration date. Each share of preferred stock was automatically converted into one share of common stock upon the closing of the Issuer's initial public offering of its common stock.
More from Atea Pharmaceuticals, Inc.
Proxy Solicitation & Information Statement
2026
Apr 27
Major Shareholding Notification
2026
Feb 9
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Director's Dealing
2026
Feb 3
Earnings Release
2026
Jan 8
Major Shareholding Notification
2025
Dec 5